# Timothy P. Hughes

Source: https://onco.cc/people/timothy-hughes/  
OnCo record `timothy-hughes` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Defined molecular response monitoring in CML and showed that many patients can safely stop imatinib.

## Summary

Timothy Hughes led the molecular monitoring analyses of the IRIS trial that established BCR-ABL1 quantitative PCR and the International Scale as the way to track chronic myeloid leukaemia, and co-led ENESTnd (nilotinib) and the studies of treatment-free remission showing about half of patients in deep molecular response can stop tyrosine kinase inhibitors. He has chaired the International CML Foundation.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: cml; molecular-monitoring; australia
- Role: Consultant Haematologist, Royal Adelaide Hospital; Cancer Theme Leader, South Australian Health and Medical Research Institute
- Specialisms: Chronic myeloid leukaemia; Molecular monitoring; Treatment-free remission; Tyrosine kinase inhibitors

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Hughes%20TP%5BAuthor%5D%20chronic%20myeloid%20leukemia

## Connected records

- cancers: [Chronic myeloid leukaemia (CML)](https://onco.cc/cancers/cml/)
- technologies: [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Imatinib](https://onco.cc/drugs/imatinib/)
- institutions: [Royal Adelaide Hospital](https://onco.cc/institutions/royal-adelaide-hospital/)
- key papers: [IRIS: imatinib versus interferon plus cytarabine as first treatment for chronic myeloid leukaemia](https://onco.cc/key-papers/paper-iris-imatinib-nejm-2003/)

---
JSON: https://onco.cc/api/v1/entities/timothy-hughes.json